Clinical Trials Handbook: Design and Conduct

Clinical Trials Handbook: Design and Conduct

Volumn , Issue , 2012, Pages

  Meinert, Curtis L ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891584996     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118422878     Document Type: Book

References (104)

1. ADAPT Research Group: Alzheimer's Disease Anti-inflammatory Prevention Trial: Design, methods, and baseline results. Alzheimer's & Dementia 2009; 5: 93-104.
2. Aickin M: A program for balancing the allocation of subjects to treatment in a clinical trial. Computers and Biomedical Research 1982; 15: 519-524.
3. Bayes T: An essay towards solving a problem in the doctrine of chances. (Reproduced in Biometrika 45:296-315, 1958.) Philos Trans R Soc Lond 1763; 53: 370-418.
4. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schultz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 1996; 276: 637-639.
5. Boissel J-P, Collet J-P, Moleur P, Haugh M: Surrogate endpoints: A basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-244.
6. Brain Resuscitation Clinical Trial II Study Group: A randomized clinical trial of calcium entry blocker administration to comatose survivors of cardiac arrest: Design, methods and patient characteristics. Control Clin Trials 1991; 12: 525-545.
7. Brittain E, Wittes J: The run-in period in clinical trials. Control Clin Trials 1990; 11: 327-338.
8. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink Jr RD, Sawin HS, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH Group: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-955.
9. Canner PL: Monitoring clinical trial data for evidence of adverse or beneficial treatment effects. INSERM 1977; 76: 131-149.
10. Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
11. Childhood Asthma Management Program Research Group: The Childhood Asthma Management Program (CAMP): Design, rationale, and methods. Control Clin Trials 1999; 20: 91-120.
12. Chow S-C, Chang M: Adaptive design methods in clinical trials-A review. Orphanet J Rare Dis 2008 3:11.
13. Christian MC, McCabe MS, Korn EL, Abrams JS, Kaplan RS, Friedman MA: The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. N Eng J Med 1995; 333: 1469-1574.
14. Cornfield J: The Bayesian outlook and its application (including discussion by S Geisser, HO Hartley, O Kempthrone, H Rubin). Biometrics 1969; 25: 617-657.
15. Cornfield J: Sequential trials, sequential analysis and the likelihood principle. Am Statistician 1966; 20: 18-23.
16. Coronary Drug Project Research Group: Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 1038-1041.
17. Coronary Drug Project Research Group: Aspirin in coronary heart disease. J Chron Dis 1976; 29: 625-642.
18. Coronary Drug Project Research Group: The Coronary Drug Project: Design, methods, and baseline results. Circulation 1973; 47(Suppl I):I-1-I-50.
19. Criner GJ Editor: National Emphysema Treatment Trial. (compendium of 34 parts ) Proc Am Thorac Soc 2008; 5: 379-574.
20. Davis KB, Fisher L, Gillespie MJ, Pettinger M: A Test of the National Death Index Using the Coronary Artery Surgery Study (CASS). Control Clin Trials 6: 179-191, 1985.
21. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJPM, Schroeder TV, Sox HC, Van Der Weyden MB: Is this clinical trial fully registered?-A statement from the International Committee of Medical Journal Editors. N Engl Med 2005; 352: 2436-2438.
22. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJPM, Schroeder TV, Sox HC, Van Der Weyden MB: Clinical Trial Registration: A Statement From the International Committee of Medical Journal Editors. JAMA 2004; 292:1363-1364.
23. DeMets DL, Lan KKG: Interim analysis: The alpha spending function approach. Stat Med 1994; 13: 1341-1352.
24. Department of Health and Human Services: HIPAA Administrative Simplification: Standard Unique Health Identifier for Health Care Providers (final rule). Federal Register 23 January 2004; 69: 3434-3469.
25. Department of Health and Human Services; Office for Civil Rights: Standards for privacy of individually identifiable health information (Unofficial version) (45 CFR Parts 160 and 164): Regulation text (28 Dec 2000: as amended: Part 160 (31 May 2002); Parts 160, 164 (14 Aug 2002); 31 pages; Oct 2002.
26. Diabetic Retinopathy Study Research Group: Diabetic Retinopathy Study: Report Number 6. Design, methods, and baseline results. Invest Ophthalmol Vis Sci 1981; 21: 149-209.
27. Diggle P, Kenward MG: Informative drop-out in longitudinal data analysis. Appl Statist 1994; 43: 49-93.
28. Dunnett CW: A multiple comparison procedure for comparing several treatments with a control. JASA 1955; 50: 1096-1121.
29. Dupont WD: Sequential stopping rules and sequentially adjusted p-values; Does one require the other? Control Clin Trials 1983; 4: 3-10.
30. Edwards AWF: Likelihood: An account of the Statistical Likelihood Concept of Likelihood and its Application to Scientific Inference. Cambridge University Press, Cambridge, 1972.
31. Food and Drug Administration: Code of Federal Regulations; 21, Parts 300-499, Revised as of April 1, 1994. Office of the Federal Register, National Archives and Records Administration, Washington, 1994.
32. Fost N, Robertson JA: Deferring consent with incompetent patients in an intensive care unit. IRB 1980; 2(7): 5-6.
33. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 1987; 317: 141-145.
34. Friedman B: A simple urn model. Commun Pure and Appl Math 1949; 2: 59-70.
35. Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT): 3. Design and methods. Control Clin Trials 1991; 12: 504-524.
36. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA, On behalf of the Chemoprevention for Barrett's Esophagus Trial Research Group: Secondary Chemoprevention of Barrett's Esophagus with Celecoxib: Results of a Randomized Trial. J Natl Cancer Inst 2007; 99: 545-557.
37. Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562-2571.
38. Hypertension Prevention Trial Research Group: The Hypertension Prevention Trial (HPT): Design, Methods, and Baseline Results (C Meinert, J Tonascia, S Tonascia, editors). Control Clin Trials 1989; 10(Suppl):1S-117S.
39. Ingelfinger FJ: Definition of ''sole contribution''. Engl J Med 1969; 281: 676-677.
40. Institute of Medicine Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials: Review of the Fialuridine (FIAU) Clinical Trials. National Academy Press, Washington, 1995.
41. International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997; 336: 309-315.
42. Katz J: Experimentation with Human Beings. Russell Sage Foundation, New York, 1972.
43. Klimt CR, Knatterud GL, Stamler J, Meier P: Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986; 7: 251-269.
44. Lachin JM, Marks JW, Schoenfield LJ, and The NCGS Protocol Committee ( Tyor MP, Bennett PH, Grundy SM, Hardison WGM, Shaw LW, Thistle JL, Vlahcevic ZR, and The National Cooperative Gallstone Study Group): Design and Methodological Considerations in the National Cooperative Gallstone Study: A Multicenter Clinical Trial. Control Clin Trials 1981; 2: 177-230.
45. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, Haug C, Hebert PC, Kotzin S, Marusic A, Sahmi P, Schroeder TV, Sox HC, Van Der Weyden MB, Verheugt FWA: Clinical trial registration: Looking back and moving ahead. Ann Intern Med 2007; 147: 275-277.
46. Levine RJ: Deferred consent. Control Clin Trials 1991; 12: 546-550.
47. Levine RJ: Ethics and Regulation of Clinical Research, 2nd ed. Yale University Press, New Haven, 1988.
48. Macular Photocoagulation Study Group: Argon laser photocoagulation for ocular histoplasmosis: Results of a randomized clinical trial. Arch Ophthalmol 1983; 101: 1347-1357.
49. Macular Photocoagulation Study Group: Argon laser photocoagulation for ideopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol 1983; 101: 1358-1361.
50. Macular Photocoagulation Study Group: Argon laser photocoagulation for senile macular degeneration: Results of a randomized clinical trial. Arch Ophthalmol 1982; 100: 912-918.
51. Martin BK, Meinert CL, Breitner JCS for the ADAPT Research Group: Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials 2002; 23: 93-99.
52. Meinert CL: Clinical Trials: Design, Conduct, and Analysis, 2nd ed. Oxford University Press, New York, 2012.
53. Meinert CL: An Insider's Guide to Clinical Trials (279 pages). Oxford University Press, New York, 2011.
54. Meinert CL: Redesign of trials under different enrollment mixes. Statist Med 1999; 18: 241-251.
55. Meinert CL: Masked monitoring in clinical trials-Blind stupidity? N Engl J Med 1998; 338: 1381-1382.
56. Meinert CL: IRBs and randomized clinical trials. IRB 1998; 20: 9-12.
57. Meinert CL: Clinical trials and treatment effects monitoring (with discussion). Control Clin Trials 1998; 19: 515-543.
58. Meinert CL: Clinical Trials Dictionary: Terminology and Usage Recommendations; The Johns Hopkins Center for Clinical Trials, Baltimore, 1996.
59. Meinert CL: An open letter to the FDA regarding changes in reporting procedures for drugs and biologics proposed in the wake of the FIAU tragedy. Control Clin Trials 1996; 17: 273-284.
60. Meinert CL, Tonascia S: Clinical Trials: Design, Conduct, and Analysis. Oxford University Press, New York, 1986.
61. Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465-1477.
62. National Emphysema Treatment Trial Research Group: Rationale and design of the National Emphysema Treatment Trial (NETT): A prospective randomized trial of lung volume reduction surgery. Chest 1999; 116: 1750-1761.
63. National Heart, Lung, and Blood Institute: Clinical coordinating center for lung volume reduction surgery for emphysema. RFP-NIH-NHLBI-HR-97-01, Bethesda, 1997.
64. National Heart, Lung, and Blood Institute: Clinical Coordinating Center for the Study of a Childhood Management Program (CAMP). RFP-NIH-NHLBI-HR-90-12, Bethesda, 1990.
65. Nutton V: What's in an oath? J Royal Coll of Phys of London 1995; 29: 518-524.
66. Office for Protection from Research Risks: Code of Federal Regulations, Title 45: Public Welfare, Part 46: Protection of Human Subjects. Department of Health and Human Services, National Institutes of Health, Bethesda, Md, (revised) 18 June 1991.
67. Persantine-Aspirin Reinfarction Study Research Group: Persantine and aspirin in coronary heart disease. Circulation 1980; 62: 449-461.
68. Physicians' Health Study Research Group Steering Committee: Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318: 262-264.
69. Pocock SJ: Clinical Trials: A Practical Approach. John Wiley and Sons, Chichester, 1983.
70. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Statistics in Medicine 1989; 8: 431-440.
71. Robbins H: A sequential decision problem with finite memory. Proc Natl Acad Sci 1956; 42: 920-923.
72. Robbins H: Some aspects of the sequential design of experiments. Bull Am Mathematics Soc 1952; 58: 527-535.
73. Robin ED, McCauley RF: Cultural lag and the Hippocratic Oath. Lacent 1995; 345: 1422-1424.
74. Roethlisberger FJ, Dickson WJ: Management and the Worker. John Wiley & Sons, New York, 1964.
75. Schlant RC, Forman S, Stamler J, Canner PL: The natural history of coronary heart disease: Prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project. Circulation 1982; 66: 401-414.
76. Schoenfield LJ, Lachin JM, The Steering Committee ( Baum RA, Habig RL, Hanson RF, Hersh T, Hightower NC Jr, Hoffmann AF, Lasser EC, Marks JW, Mekhjian H, Okun R, Schaefer RA, Shaw L, Soloway RD, Thistle JL, Thomas FB, Tyor MP) and the National Cooperative Gallstone Study Group: Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: The National Cooperative Gallstone Study. Ann Intern Med 1981; 95: 257-282.
77. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3294.
78. Shimm DS, Spece RG: Ethical issues and clinical trials. Drugs 1993; 46: 579-584.
79. Simon R: Adaptive treatment assignment method and clinical trials. Biometrics 1977; 33: 743-749.
80. Studies of the Ocular Complications of AIDS Research Group: SOCA General Handbook, https://jhuccs1.us/soca/SOCAgenhandbook/socagenhndbk.pdf, accessed (6:38am Saturday) 10 December 2011.
81. Studies of the Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir CMV Retinitis Trial. Am J Ophthalmol 2001; 131: 457-467.
82. Studies of the Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Monoclonal Antibody Cytomegalovirus Retinitis Trial. Arch Ophthalmol 1997; 115: 1528-1536.
83. Studies of the Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial. A randomized, controlled trial. Ann Intern Med 1997; 126: 264-274.
84. Studies of the Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The Cytomegalovirus Retreatment Trial. Arch Ophthalmol 1996; 114: 23-33.
85. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group (ACTG): Studies of ocular complications of AIDS foscarnet-ganciclovir cytomegalovirus retinitis trial: 1. Rationale, design, and methods. Control Clin Trials 1992; 13: 22-39.
86. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213-220.
87. Taves DR: Minimization: A new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974; 15: 443-453.
88. United States Congress (103rd; 1st session): NIH Revitalization Act of 1993, 42 USC § 131 (1993); Clinical Research Equity Regarding Women and Minorities; Part I: Women and Minorities as Subjects in Clinical Research. 1993.
89. University Group Diabetes Program Research Group: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VIII. Evaluation of insulin therapy: Final report. Diabetes 1982; 31(Suppl 5): 1-81.
90. University Group Diabetes Program Research Group: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240: 37-42.
91. University Group Diabetes Program Research Group: A Study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes:V. Evaluation of Phenformin therapy. Diabetes 1975; 24(Suppl 1): 65-184.
92. University Group Diabetes Program Research Group: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: IV. A preliminary report on phenformin results. JAMA 1971; 217: 777-784.
93. University Group Diabetes Program Research Group: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: 1. Design, methods, and baseline characteristics. Diabetes 1970; 19(Suppl 2): 747-783.
94. University Group Diabetes Program Research Group: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. Diabetes 1970; 19(Suppl 2): 785-830.
95. Webster's Eleventh New Collegiate Dictionary. Merriam-Webster Inc, Springfield, Mass, 2009.
96. Webster's Ninth New Collegiate Dictionary. Merriam-Webster Inc, Springfield, Mass, 1991.
97. Wei LJ, Lachin JM: Properties of the urn randomization in clinical trials. Control Clin Trials 1988; 9: 345-364.
98. Wei LJ: A class of designs for sequential clinical trials. JASA 1977; 72: 382-386.
99. Winau R: The hippocratic oath and ethics in medicine. Forensic Sci Int 1994; 69: 285-289.
100. Wittes J, Lakatos E: Surrogate endpoints in clinical trials: Cardiovascular diseases. Statistics in Medicine 1989; 8: 415-425.
101. Wright JT Jr, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R for the AASK Pilot Study Investigators: Design and Baseline Characteristics of Participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 16: 3S-16S.
102. Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266: 93-98, 1991.
103. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DAB: Issues in the registration of clinical trials. JAMA 2007; 297: 2112-2120.
104. Zelen M: Play the winner rule and the controlled clinical trial. JASA 1969; 64: 131-146.